top of page


Johnson & Johnson agrees to acquire Ollin Biosciences for up to $3.3 billion to expand retinal disease pipeline
Johnson & Johnson has agreed to acquire ophthalmology biotechnology company Ollin Biosciences for up to approximately $3.3 billion, adding a Phase III retinal disease antibody programme alongside a separate $750 million Blackstone development funding arrangement.

nuaxia
6 hours ago2 min read


FDA declines approval of Summit and Akeso's ivonescimab for EGFR-mutated lung cancer
The FDA has issued a Complete Response Letter for Summit Therapeutics' ivonescimab in EGFR-mutated lung cancer after the HARMONi trial demonstrated a progression-free survival benefit but did not establish a statistically significant overall-survival benefit.

nuaxia
1 day ago2 min read


European Commission approves Tecvayli monotherapy from first relapse in multiple myeloma
The European Commission has approved Johnson & Johnson's Tecvayli monotherapy from first relapse in multiple myeloma, moving the bispecific antibody into an earlier treatment setting.

nuaxia
Oct 272 min read


Bolt Biotherapeutics acquires Prana Therapies alongside $120 million financing to advance inflammatory disease pipeline
Bolt Biotherapeutics has acquired Prana Therapies in a stock-for-stock transaction and arranged $120 million in financing to advance a new inflammatory disease pipeline.

nuaxia
Oct 262 min read


Roche and Dualitas enter bispecific discovery collaboration worth more than $1bn
Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.

nuaxia
Sep 182 min read
bottom of page